During the ablation, the patient was asked to concentrate on a fixation light mounted coaxially to the optical selleck products axis of the excimer laser. The time needed for treatment is approximately 1.2?seconds per dioptre of myopia. After photoablation, the interface was rinsed with balanced salt solution (BSS?; Alcon, Fort Worth, TX, USA) and the flap was repositioned. The postoperative therapy consisted of Isopto-Max? (Alcon, Freiburg, Germany) eye drops (neomycin, polymyxin-B and dexamethasone) four times a day for 1?week and artificial tears (Vismed; TRB Chemedica, Haar, Germany) whenever needed. All treatments were based on manifest refraction with the target refraction of emmetropia. No nomogram adjustment was applied Gefitinib in vivo in this study. Preoperatively, calibration tests of the excimer laser (including energy measurements, ablation of test target, scanning mirror alignment check and testing of the video eye tracker) were performed as recommended by the manufacturer of the laser. Patients were examined 1 and 3?days as well as 1?week after surgery to detect possible complications. Clinical results concerning safety, efficacy, predictability and stability were analysed at the follow-up examinations 1, 3 and 6?months after surgery. The standard graphs for reporting refractive surgery according to Waring (Waring 2000) were created using the program Datagraph-med (version 2.8; Ingenieurb??ro Pieger GmbH, Wendelstein, Germany). Twenty eyes of 11 patients with myopia or myopic astigmatism were included in this noncontrolled, nonrandomized, observational prospective study. Table?1 shows the patients?? preoperative data. No patient was lost to follow-up. Flap creation, photoablation and repositioning of the flap were uneventful in all eyes. The corneas of all eyes remained clear during and after photoablation. Neither Forskolin immediately after the procedure nor at any of the postoperative examinations were there signs of corneal opacities, increased postsurgical inflammatory reaction in the early postoperative period, diffuse lamellar keratitis (DLK) or thermal damage upon slit lamp microscopy. Table?2 shows the refraction pre- and postoperatively (1, 3 and 6?months after surgery). No re-treatment had to be performed, because there were no major under- or overcorrections (Fig.?1). Six months after LASIK, 95% of the eyes were within ??0.5?D and all eyes within ??1.0?D of the intended correction (Fig.?2). The defocus equivalent refraction was ??0.5?D in 90% and ??1.0?D in 100% of the eyes 6?months postoperatively (Fig.?3). The refraction stayed stable over time (Fig.?4); 95% of the eyes changed <0.5?D from 1?month to 6?months after surgery. UCDVA was 20/30 or better in all eyes on the first postoperative day. The UCDVA 1, 3 and 6?months after surgery is displayed in Fig.?5. UCDVA was 20/20 or better in 85% of the eyes and 20/25 or better in all eyes 6?months postoperatively. Fig.